Literature DB >> 26602889

Factors Influencing Readmission after Elective Ureteroscopy.

Jonathan Bloom1, Gerald Matthews2, John Phillips2.   

Abstract

PURPOSE: Ureteroscopy is increasingly used to manage nephrolithiasis, upper urinary tract urothelial carcinoma and other urological conditions. In this study we determine the rate of readmission and emergency department visits after ureteroscopy in an underserved population, as well as factors associated with these unplanned visits.
MATERIALS AND METHODS: A retrospective chart review from 2010 to 2014 of all elective ureteroscopies was conducted at a single tertiary hospital serving an underserved population in a major metropolis. Demographic, operative and discharge characteristics were collected and analyzed.
RESULTS: A total of 276 ureteroscopies were performed with 15.6% presenting to the emergency department within 30 days. Overall 5.8% were readmitted. Readmitted patients were more likely to have hypertension (OR 3.64, p=0.02), asthma or chronic obstructive pulmonary disease (OR 5.54, p=0.001), 2 or more comorbidities (OR 3.65, p=0.12), or a complication associated with ureteroscopy (OR 7.27, p=0.007). The patients who sought care in the emergency department after ureteroscopy were less likely to have had a ureteral stent in place before ureteroscopy (OR 0.35, p=0.017) or an endoscopic urological procedure within the last 30 days (OR 0.35, p=0.045). About two-thirds of patients who presented to the emergency department complained of pain alone, while the most common complaints for readmitted patients were fever and pain (43.8%).
CONCLUSIONS: The majority of emergency department visits after ureteroscopy were due to pain. These patients were less likely to have a preoperative ureteral stent placed or a history of recent urological procedures. Readmission rates were associated with overall comorbidities and complications.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  comorbidity; emergency service, hospital; patient readmission; stents; ureteroscopy

Mesh:

Year:  2015        PMID: 26602889     DOI: 10.1016/j.juro.2015.11.030

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Comparison of 30-day emergency department bouncebacks after pediatric versus adult urologic surgery.

Authors:  Courtney L Shepard; Julian Wan
Journal:  J Pediatr Urol       Date:  2017-06-20       Impact factor: 1.830

2.  Analysis of factors affecting re-admission after retrograde intrarenal surgery for renal stone.

Authors:  Tae Jin Kim; In Jae Lee; Jung Keun Lee; Hak Min Lee; Chang Wook Jeong; Sung Kyu Hong; Seok-Soo Byun; Jong Jin Oh
Journal:  World J Urol       Date:  2018-10-03       Impact factor: 4.226

3.  Urology Consultation and Emergency Department Revisits for Children with Urinary Stone Disease.

Authors:  Jane T Kurtzman; Lihai Song; Michelle E Ross; Charles D Scales; David I Chu; Gregory E Tasian
Journal:  J Urol       Date:  2018-02-21       Impact factor: 7.450

4.  Reasons for early readmission after percutaneous nephrolithotomy and retrograde intrarenal surgery.

Authors:  Sarp Korcan Keskin; Yavuz Onur Danacioglu; Turgay Turan; Ramazan Gokhan Atis; Cengiz Canakci; Turhan Caskurlu; Ali Erol; Asif Yildirim
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-08-19       Impact factor: 1.195

5.  Infection-related hospitalization following ureteroscopic stone treatment: results from a surgical collaborative.

Authors:  Adam Cole; Jaya Telang; Tae-Kyung Kim; Kavya Swarna; Ji Qi; Casey Dauw; Brian Seifman; Mazen Abdelhady; William Roberts; John Hollingsworth; Khurshid R Ghani
Journal:  BMC Urol       Date:  2020-11-03       Impact factor: 2.264

6.  Secondary signs on preoperative CT as predictive factors for febrile urinary tract infection after ureteroscopic lithotripsy.

Authors:  Jin Woo Kim; You Jin Lee; Yun-Sok Ha; Jun Nyung Lee; Hyun Tae Kim; So Young Chun; Bum Soo Kim
Journal:  BMC Urol       Date:  2020-08-27       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.